What is the recommended first‑line treatment for primary open‑angle glaucoma and the subsequent medication options if target intra‑ocular pressure is not achieved?

First-Line Treatment for Primary Open-Angle Glaucoma

Prostaglandin analogs are the recommended first-line medical treatment for primary open-angle glaucoma, with bimatoprost, latanoprost, and travoprost being the most effective options for lowering intraocular pressure. 1, 2

Initial Treatment Goal and Strategy

• Target a 20-30% reduction in IOP from baseline, adjusting based on disease severity and progression 1
• Lowering IOP is the only proven intervention to prevent progression and visual loss, even in patients with normal-tension glaucoma 1

First-Line Medication Options (Ranked by Efficacy)

The most effective first-line topical medications at 3 months, based on network meta-analysis of 114 randomized trials with over 20,000 participants 2:

1. Bimatoprost 0.03%: Mean IOP reduction of 5.61 mmHg 2
2. Latanoprost: Mean IOP reduction of 4.85 mmHg 2
3. Travoprost: Mean IOP reduction of 4.83 mmHg 2
4. Tafluprost: Mean IOP reduction of 4.37 mmHg 2

While bimatoprost shows slightly superior IOP reduction, the differences between these prostaglandin analogs are small (less than 1 mmHg) and may not be clinically meaningful 2. All three major prostaglandins (bimatoprost, latanoprost, travoprost) demonstrate comparable efficacy and tolerability 3.

Alternative First-Line Consideration

• Selective laser trabeculoplasty (SLT) is increasingly used as first-line treatment, particularly by U.S. physicians with larger glaucoma practices, though approximately 74% of ophthalmologists still prefer topical medications initially 4

Second-Line Options When Target IOP Not Achieved

When monotherapy fails to achieve target IOP, add medications from different drug classes 5:

Beta-Blockers (if not used first-line)

• Timolol: Mean IOP reduction of 3.70 mmHg 2
• Levobunolol: Mean IOP reduction of 4.51 mmHg 2

Alpha-2 Agonists

• Brimonidine: Mean IOP reduction of 3.59 mmHg 2

Topical Carbonic Anhydrase Inhibitors

• Dorzolamide: Mean IOP reduction of 2.49 mmHg 2
• Brinzolamide: Mean IOP reduction of 2.42 mmHg 2

Combination Therapy Strategy

When adding a second medication, combine drugs from different classes (e.g., prostaglandin + beta-blocker, or prostaglandin + carbonic anhydrase inhibitor) to achieve additive IOP-lowering effects 5. The most commonly studied and effective combinations involve:

• Prostaglandin analog + beta-blocker 5
• Prostaglandin analog + carbonic anhydrase inhibitor 5

Common Pitfalls and Caveats

• Prostaglandin side effects include conjunctival hyperemia, periocular skin pigmentation, iris darkening, and eyelash growth 6
• Timing of IOP measurements matters: Assess IOP at different times of day to capture diurnal fluctuations, as all three major prostaglandins effectively reduce both mean IOP and diurnal fluctuations 3
• Consider patient-specific factors: While efficacy differences between top prostaglandins are minimal, individual patient response, side effect profile, and cost should guide selection 2
• Fixed-combination products may differ from concomitant use of separate medications in terms of peak/trough timing effects 5

Progression to Third-Line and Beyond

If dual therapy fails to achieve target IOP, add a third agent from a different class (triple therapy with prostaglandin + beta-blocker + carbonic anhydrase inhibitor or alpha-agonist) 5. Beyond medical therapy, consider laser trabeculoplasty or incisional surgery 1.